Prevalence and Risk Factors for Non-Hepatic Cancers in Cirrhosis: A Cross-Sectional Study

Abstract

Background

Patients with liver cirrhosis are at a higher risk of developing non-hepatic cancers (NHC) than general population. Considering that NHC causes poor outcomes, it is necessary to explore the prevalence of NHC in such patients and identify its associated risk factors.

Methods

Patients with a diagnosis of liver cirrhosis who were consecutively admitted to our hospital between January 1, 2010 and June 30, 2014 were retrospectively screened. They were divided into NHC, primary liver cancer (PLC), and non-cancer groups. After adjusting for age and sex, logistic regression analyses were performed to explore the risk factors of NHC in patients with cirrhosis. Adjusted odds ratios (aORs) with their 95% confidence intervals (CIs) were calculated.

Results

Overall, 2509 patients with cirrhosis were included. Prevalence of NHC and PLC was 6.22% (156/2509) and 22.20% (557/2509), respectively. After adjusting for age and sex, the NHC group had a significantly higher proportion of history of smoking (aOR = 1.994; 95% CI = 1.231-3.231, P = 0.005), but lower proportions of history of encephalopathy (aOR = 0.344; 95% CI = 0.147- 0.804, P = 0.014) and history of heart disease (aOR = 0.300; 95% CI = 0.173-0.519, P < 0.001) as compared to the non-cancer group. Hepatitis B virus infection (aOR = 0.863; 95% CI = 0.581-1.281, P = 0.465), hepatitis C virus infection (aOR = 0.908; 95% CI = 0.503-1.642, P = 0.750), and alcohol abuse alone (aOR = 1.254; 95% CI = 0.779-2.017, P = 0.351) as the etiology of liver cirrhosis were not significantly associated with the risk of NHC.

Conclusions

Smoking may be associated with a higher probability of NHC in patients with cirrhosis, but the probability of NHC may be compromised by encephalopathy or heart disease.

Keywords

liver cirrhosis cancer non-hepatic cancer risk factor prevalence

Introduction

Liver cirrhosis can be caused by alcoholic liver disease and chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections.¹ It can lead to various decompensation events,² including esophagogastric variceal bleeding (EGVB), ascites, hepatic encephalopathy, and hepatorenal syndrome,³ and progress to primary liver cancer (PLC) with an annual incidence of 1.82%.⁴ Except for a major risk factor for the development of PLC,⁵ liver cirrhosis is also closely associated with the development of NHC.⁶ It has been shown that the overall risk for NHC was 2-3 times more common in patients with cirrhosis compared with the general population.⁷ HBV infection is associated with a 2.24-fold increased risk of non-Hodgkin’s lymphoma and a 1.49-fold elevated risk of gastric cancer.^8,9 Cirrhotic patients with HBV infection have an increased risk of lung, kidney, skin (squamous cell carcinoma), and thyroid cancers, as well as lymphoma and leukaemia^10,11; those with HCV infection have an increased risk of gallbladder, stomach, pancreatic, and lung cancers^11,12; and those with alcoholic cirrhosis have an increased risk of gastric, colorectal, pancreatic, and esophageal cancers.^13,14 Despite a relatively low prevalence of NHC in liver cirrhosis, it deteriorates the outcomes with a high mortality. Additionally, the presence of liver cirrhosis, especially worse liver function reserve, potentially limits the use of anticancer therapy in NHC patients. Notably, it is of importance for clinicians and patients to recognize the risk factors associated with NHC in cirrhosis, because the incidence and mortality of cancer can be effectively reduced by eliminating carcinogenic risk factors.^15,16 Age, sex, smoking, and alcohol consumption are well-known risk factors for cancer,^17,18 but few studies have explored the risk factors for NHC in patients with liver cirrhosis. Herein, we have conducted a cross-sectional study to estimate the prevalence of NHC and explore its related risk factors in patients with liver cirrhosis.

Methods

Study Design

We retrospectively collected a total of 4221 patients with liver cirrhosis who were consecutively admitted to the Department of Gastroenterology of the General Hospital of Northern Theater Command from January 1, 2010 to June 30, 2014, as previously mentioned.¹⁹ Exclusion criteria were as follows: (1) repeated admissions; (2) unclear origin of cancer; (3) a combination of hepatic and non-hepatic cancers; (4) a suspected diagnosis of cancer; and (5) the age < 18 years old at the first diagnosis of liver cirrhosis. Among the patients with repeated admissions during the study period, only their last admissions were included.

The study protocol was approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command with an approval number [Y (2024) 009] and was carried out following the guidelines of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study. This study conformed to the STROBE guidelines.²⁰ All patients’ details were de-identified.

Groups and Definitions

Cirrhotic patients were divided into NHC group, PLC group, and non-cancer group. Liver cirrhosis is diagnosed based on disease history, clinical symptoms and signs, laboratory tests, imaging, liver stiffness measurement, and histopathological examinations, if possible.²¹ NHC refers to primary malignancy diagnosed by definitive pathology or radiographic evidence, mainly including cancer of the lung, colon/rectum, non-Hodgkin’s lymphoma, esophagus, pancreas, prostate, and/or breast, etc.²² PLC is diagnosed based on dynamic CT or MRI scans. If necessary, liver histology may be obtained for further confirmation.^23,24

Data Collection

Demographic, clinical, and laboratory data at admissions were collected, including age, sex, smoking, diabetes mellitus (DM), hypertension, history of encephalopathy, history of respiratory, heart, and kidney diseases, etiology of liver cirrhosis (ie, HBV infection alone, HCV infection alone, and alcohol abuse alone), treatment of liver cirrhosis (ie, drug and surgery), red blood cell (RBC), hemoglobin (Hb), white blood cell (WBC), platelet count (PLT), total bilirubin (TBIL), albumin (ALB), serum creatinine (Scr), serum sodium (Na), and international normalized ratio (INR). Child-Pugh and model of end-stage liver disease (MELD) scores were calculated. Viral hepatitis is diagnosed by serological tests for specific viral antigens and antibodies.²⁵ Smoking focused on burning tobacco, including cigarettes, cigars, and hookah, but not e-cigarettes and smokeless tobacco products.

Statistical Analyses

All statistical analyses were performed by using SPSS version 26.0 statistical software (IBM Corp, Armonk, New York, USA). Continuous variables were expressed as mean ± standard deviation and median (range), and compared by the independent sample t-tests for normal distribution, and the Mann-Whitney U tests for non-normal distribution. The Chi-square test was used for categorical variables to analyze the difference between groups. Univariate logistic regression analysis was used to evaluate the factors associated with NHC and PLC. Odds ratios with their 95% confidence intervals (CIs) were calculated. Multivariate logistic regression analysis was further performed by adjusting for age and sex.^26,27 Given that sex is a recognized risk factor for cancer, subgroup analyses were conducted in male and female patients. A two-tailed P value of <0.05 was considered statistically significant. Participants with missing data were removed from the corresponding analyses to ensure the data completeness.

Results

Patients’ Selection

Overall, 1712 patients were excluded due to repeated admissions (n = 1686), unclear origin of cancer (n = 8), NHC complicated with PLC (n = 15), unclear diagnosis of cancer (n = 1), and age <18 years old (n = 2). Finally, 2509 patients were included (Figure 1). The prevalence of NHC and PLC was 6.22% and 22.2%, respectively. There is a consistent upward trend in the prevalence of NHC from 6.95% to 7.65%, while a gradual downward trajectory in the prevalence of PLC from 25.56% to 22.94% during the study period. The median age was 56.60 (18.57-95.13) years old.

Figure 1.

Flowchart of Patients’ Screening and Grouping. Abbreviations: NHC, Non-hepatic Cancers; PLC, Primary Liver Cancer

Characteristics of Patients

Patient characteristics are summarized in Table 1. Types of NHC, which can be observed in at least three cases, are listed in Supplemental Figure 1. The trend in the prevalence of NHC/PLC by calendar year is listed in Supplemental Figure 2.

Table 1.

Characteristics of Patients Among PLC, NHC, and Non-Cancer Groups

Variables	Non-cancer group (n = 1796)				PLC group (n = 557)		P value^a	NHC group (n = 156)		P value^b
Variables	No. pts	Mean ± SD and median (range) or frequency (percentage)			No. pts	Mean ± SD and median (range) or frequency (percentage)	P value^a	No. pts	Mean ± SD and median (range) or frequency (percentage)	P value^b
Demographics
Age (years)	1796	56.54 ± 12.11;	557			57.99 ± 10.93;	0.022	156	63.34 ± 11.38;	<0.001
Age (years)	1796	56.10 (18.57-95.13)	557			57.06 (23.80-88.29)	0.022	156	62.86 (40.00-87.82)	<0.001
Sex (male)	1796	1194 (66.50%)	557			445 (79.90%)	<0.001	156	62 (39.70%)	<0.001
Smoking (%)	1129	364 (32.20%)	345			123 (35.70%)	0.238	110	37 (33.60%)	0.765
Diabetes (%)	686	140 (20.40%)	555			93 (16.80%)	0.101	155	28 (18.10%)	0.510
Hypertension (%)	686	116 (16.90%)	555			76 (13.70%)	0.119	155	40 (25.80%)	0.010
History of encephalopathy (%)	1796	147 (8.20%)	555			24 (4.30%)	0.002	155	6 (3.90%)	0.055
History of respiratory (%)	1796	108 (6.00%)	555			13 (2.30%)	0.001	155	7 (4.50%)	0.448
History of heart disease (%)	1796	351 (19.50%)	556			27 (4.90%)	<0.001	156	16 (10.30%)	0.005
History of kidney disease (%)	1796	129 (7.20%)	555			8 (1.40%)	<0.001	155	5 (3.20%)	0.062
Etiology of liver cirrhosis
HBV infection alone (%)	1796	510 (28.40%)			557	272 (48.80%)	<0.001	156	37 (23.70%)	0.212
HCV infection alone (%)	1796	125 (7.00%)			557	41 (7.40%)	0.747	156	14 (9.00%)	0.348
Alcohol abuse alone (%)	1796	431 (24.00%)			557	59 (10.60%)	<0.001	156	28 (17.90%)	0.087
Child-Pugh class	1639	7.59 ± 2.20;			489	7.43 ± 2.17;	0.159	140	7.45 ± 1.95;	0.725
Child-Pugh class	1639	7.00 (5.00-15.00)			489	7.00 (5.00-14.00)	0.159	140	7.00 (5.00-13.00)	0.725
Child-Pugh class A (%)	1639	620 (37.80%)			489	199 (40.70%)	0.253	140	48 (34.30%)	0.406
Child-Pugh class B (%)	1639	703 (42.90%)			489	205 (41.90%)	0.704	140	71 (50.70%)	0.073
Child-Pugh class C (%)	1639	316 (19.30%)			489	85 (17.40%)	0.346	140	21 (15.00%)	0.215
MELD score	1298	11.79 ± 6.02;			421	11.81 ± 6.19;	0.706	125	11.44 ± 5.91;	0.503
MELD score	1298	9.54 (6.43-37.54)			421	9.20 (6.43-40.00)	0.706	125	9.28 (6.43-40.00)	0.503
Surgical treatment (%)	1788	387 (21.60%)			554	82 (14.80%)	0.036	154	13 (8.40%)	0.006
Laboratory parameters
RBC (10¹²/L)	1765	3.22 ± 0.86;		545		3.52 ± 0.88	<0.001	154	3.39 ± 0.77	0.009
RBC (10¹²/L)	1765	3.20 (0.93-6.78)		545		3.60 (0.79-6.08)	<0.001	154	3.43 (1.18-5.26)	0.009
WBC (10⁹/L)	1770	5.49 ± 4.05;		544		6.30 ± 4.57;	<0.001	154	6.05 ± 3.82;	0.005
WBC (10⁹/L)	1770	4.40 (0.30-46.10)		544		5.20 (0.50-55.20)	<0.001	154	4.95 (1.10-23.40)	0.005
Hb (g/L)	1768	99.15 ± 30.62;		545		110.49 ± 28.90;	<0.001	154	104.08 ± 23.57;	0.025
Hb (g/L)	1768	98.00 (27.00-292.00)		545		113.00 (15.00-170.00)	<0.001	154	108.00 (51.00-153.00)	0.025
ALB (g/L)	1713	32.58 ± 7.32		530		33.13 ± 7.18;	0.135	147	33.25 ± 6.90;	0.485
ALB (g/L)	1713	32.70 (0.40-52.80)		530		32.90 (11.70-53.90)	0.135	147	32.30 (16.40-52.60)	0.485
PLT (10⁹/L)	1765	99.40 ± 72.65;		545		114.86 ± 69.22;	<0.001	154	127.43 ± 88.97;	<0.001
PLT (10⁹/L)	1765	79.00 (3.00-592.00)		545		99.00 (17.00-607.00)	<0.001	154	100.00 (5.00-487.00)	<0.001
TBIL (μmol/L)	1769	46.09 ± 76.68		538		57.46 ± 88.68;	0.001	153	54.61 ± 77.59;	0.962
TBIL (μmol/L)	1769	22.50 (1.90-903.00)		538		25.80 (4.50-642.10)	0.001	153	21.40 (1.40-454.70)	0.962
Scr (umol/L)	1717	87.23 ± 116.62;		529		75.10 ± 65.97;	0.519	152	71.56 ± 47.97;	0.341
Scr (umol/L)	1717	61.00 (15.00-1473.00)		529		61.00 (21.00-1189.00)	0.519	152	59.00 (28.00-366.00)	0.341
Na (mmol/L)	1738	138.48 ± 4.69;		528		137.27 ± 4.99;	<0.001	153	137.45 ± 5.06;	0.020
Na (mmol/L)	1738	139.10 (116.40-160.80)		528		138.00 (112.10-147.90)	<0.001	153	138.50 (116.80-147.40)	0.020
INR	1715	1.36 ± 0.58;		515		1.27 ± 0.46;	<0.001	147	1.20 ± 0.31;	<0.001
INR	1715	1.23 (0.76-13.40)		515		1.15 (0.76-4.70)	<0.001	147	1.12 (0.79-2.42)	<0.001

Abbreviations: No. pts, numbers of patients; SD, standard deviation; PLC, primary liver cancer; NHC, non-hepatic cancers; MELD, model of end-stage liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; RBC, red blood cell; Hb, hemoglobin; WBC, white blood cell; PLT, platelet count; TBIL, total bilirubin; ALB, albumin; Scr, serum creatinine; Na, natrium; INR, international normalized ratio. Bold indicates statistically significant of P-value.

^aPLC group vs non-cancer group.

^bNHC group vs non-cancer group.

In the NHC group, the average age was 63.34 ± 11.38 years, and 62 (39.70%) patients were male. 37 (33.60%) patients had a history of smoking. 28 (18.10%) patients had DM, and 40 (25.80%) had hypertension. HBV infection alone was the most common etiology of liver cirrhosis (n = 37, 23.70%), followed by alcohol abuse alone (n = 28, 17.90%).

In the PLC group, the average age was 57.99 ± 10.93 years, and 445 (79.90%) patients were male. 123 (35.70%) patients had a history of smoking. 93 (16.80%) patients had DM, and 76 (13.70%) had hypertension. HBV infection alone was the most common etiology of liver cirrhosis (n = 272, 48.80%), followed by alcohol abuse alone (n = 59, 10.60%).

In the non-cancer group, the average age was 56.54 ± 12.11 years, and 1194 (66.50%) patients were male. 364 (32.20%) patients had a history of smoking. 140 (20.40%) patients had DM, and 116 (16.90%) had hypertension. HBV infection alone (n = 510, 28.40%) was the most common etiology of liver cirrhosis, followed by alcohol abuse alone (n = 431, 24.00%).

Factors Associated With NHC

Univariate logistic regression analysis showed that older age (OR = 1.047; 95% CI = 1.033-1.062, P < 0.001) and hypertension (OR = 1.709; 95% CI = 1.133-2.579, P = 0.011) were significantly associated with a higher risk of NHC, but male (OR = 0.333; 95% CI = 0.238-0.465, P < 0.001) and history of heart disease (OR = 0.474; 95% CI = 0.279-0.805, P = 0.006) were significantly associated with a lower risk of NHC (Table 2). After adjusting for sex and age, multivariate logistic regression analysis showed that history of smoking (aOR = 1.994; 95% CI = 1.231-3.231, P = 0.005) was independently associated with a higher risk of NHC, but history of encephalopathy (aOR = 0.344; 95% CI = 0.147-0.804, P = 0.014) and heart disease (aOR = 0.300; 95% CI = 0.173-0.519, P < 0.001) were independently associated with a lower risk of NHC (Table 2).

Table 2.

Logistic Regression Analyses of Risk Factors of NHCb

Variables	Univariate analysis		Multivariate analysis^a
Variables	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Demographics
Age (years)	1.047 (1.033-1.062)	<0.001	—
Sex (male vs female)	0.333 (0.238-0.465)	<0.001	—
History of smoking (yes vs no)	1.065 (0.704-1.613)	0.765	1.994 (1.231-3.231)	0.005
Past medical history
Diabetes (yes vs no)	0.860 (0.549-1.348)	0.510	0.765 (0.485-1.206)	0.249
Hypertension (yes vs no)	1.709 (1.133-2.579)	0.011	1.372 (0.896-2.100)	0.145
History of kidney disease (yes vs no)	0.431 (0.174-1.069)	0.069	0.414 (0.165-1.035)	0.059
History of encephalopathy (yes vs no)	0.452 (0.196-1.039)	0.062	0.344 (0.147-0.804)	0.014
History of respiratory disease (yes vs no)	0.739 (0.338-1.617)	0.449	0.571 (0.257-1.271)	0.170
History of heart disease (yes vs no)	0.474 (0.279-0.805)	0.006	0.300 (0.173-0.519)	<0.001
Etiology of liver cirrhosis
HBV infection alone (yes vs no)	0.784 (0.535-1.150)	0.213	0.863 (0.581-1.281)	0.465
HCV infection alone (yes vs no)	1.318 (0.739-2.350)	0.349	0.908 (0.503-1.642)	0.750
Alcohol abuse alone (yes vs no)	0.693 (0.454-1.058)	0.089	1.254 (0.779-2.017)	0.351
Duration of liver cirrhosis (years)
<5	0.844 (0.546-1.304)	0.444	0.863 (0.555-1.343)	0.514
5-9	0.848 (0.465-1.547)	0.592	0.951 (0.516-1.751)	0.872
10-15	1.081 (0.386-3.022)	0.882	1.275 (0.450-3.613)	0.648

Abbreviations: NHC, non-hepatic cancers; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus. Bold indicates statistically significant of P-value.

^aAdjusted for sex, age.

^bNon-cancer group as a reference group.

To further analyze the impact of smoking status on NHC, we further divided patients with a history of smoking into the current and previous smokers. After adjusting for sex and age, multivariate logistic regression analysis showed that smoking status (aOR = 0.466; 95% CI = 0.197-1.101, P = 0.082) was not independently associated with a higher risk of NHC.

Factors Associated With PLC

Univariate logistic regression analysis showed that older age (OR = 1.010; 95% CI = 1.002-1.018, P = 0.012), male (OR = 2.003; 95% CI = 1.593-2.519, P < 0.001), and HBV infection alone as the etiology of liver cirrhosis (OR = 2.407; 95% CI = 1.980-2.925, P < 0.001) were significantly associated with a higher risk of PLC, but history of kidney disease (OR = 0.189; 95% CI = 0.092-0.389, P < 0.001), encephalopathy (OR = 0.507; 95% CI = 0.326-0.789, P = 0.003), respiratory disease (OR = 0.375; 95% CI = 0.209-0.672, P = 0.001), and heart disease (OR = 0.211; 95% CI = 0.141-0.315, P < 0.001) and alcohol abuse alone as the etiology of liver cirrhosis (OR = 0.375; 95% CI = 0.281-0.502, P < 0.001) were significantly associated with a lower risk of PLC (Table 3). After adjusting for sex and age, multivariate logistic regression analysis showed that HBV infection alone (aOR = 2.773; 95% CI = 2.262-3.400, P < 0.001) was independently associated with a higher risk of PLC, but alcohol abuse alone (aOR = 0.280; 95% CI = 0.208-0.377, P < 0.001), history of kidney disease (aOR = 0.182; 95% CI = 0.088-0.376, P < 0.001), encephalopathy (aOR = 0.427; 95% CI = 0.272-0.672, P < 0.001), respiratory disease (aOR = 0.325; 95% CI = 0.180-0.587, P < 0.001), and heart disease (aOR = 0.190; 95% CI = 0.126-0.287, P < 0.001) were independently associated with a lower risk of PLC (Table 3).

Table 3.

Logistic Regression Analyses of Risk Factors of PLCb

Variables	Univariate analysis		Multivariate analysis^a
Variables	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Demographics
Age (years)	1.010 (1.002-1.018)	0.012	—
Sex (male vs female)	2.003 (1.593-2.519)	<0.001	—
History of smoking (yes vs no)	1.164 (0.904-1.500)	0.239	0.928 (0.709-1.216)	0.588
Past medical history
Diabetes (yes vs no)	0.785 (0.587-1.049)	0.102	0.740 (0.544-1.007)	0.055
Hypertension (yes vs no)	0.780 (0.570-1.067)	0.120	0.802 (0.571-1.125)	0.200
History of kidney disease (yes vs no)	0.189 (0.092-0.389)	<0.001	0.182 (0.088-0.376)	<0.001
History of encephalopathy (yes vs no)	0.507 (0.326-0.789)	0.003	0.427 (0.272-0.672)	<0.001
History of respiratory disease (yes vs no)	0.375 (0.209-0.672)	0.001	0.325 (0.180-0.587)	<0.001
History of heart disease (yes vs no)	0.211 (0.141-0.315)	<0.001	0.190 (0.126-0.287)	<0.001
Etiology of liver cirrhosis
HBV infection alone (yes vs no)	2.407 (1.980-2.925)	<0.001	2.773 (2.262-3.400)	<0.001
HCV infection alone (yes vs no)	1.062 (0.736-1.532)	0.747	1.240 (0.847-1.813)	0.268
Alcohol abuse alone (yes vs no)	0.375 (0.281-0.502)	<0.001	0.280 (0.208-0.377)	<0.001
Duration of liver cirrhosis (years)
<5	1.111 (0.868-1.420)	0.404	1.108 (0.864-1.421)	0.421
5-9	1.060 (0.750-1.497)	0.743	1.088 (0.766-1.544)	0.639
10-15	1.312 (0.730-2.357)	0.364	1.400 (0.772-2.536)	0.268

Abbreviations: PLC, primary liver cancer; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus. Bold indicates statistically significant of P-value.

^aAdjusted for sex, age.

^bNon-cancer group as a reference group.

Subgroup Analyses

In male patients, univariate logistic regression analysis showed that older age (OR = 1.048; 95% CI = 1.027-1.070, P < 0.001) was significantly associated with a higher risk of NHC. After adjusting for age, multivariate logistic regression analysis showed that history of heart disease (aOR = 0.325; 95% CI = 0.126-0.834, P = 0.019) was independently associated with a lower risk of NHC (Table 4).

Table 4.

Logistic Regression Analyses of Risk Factors of NHC in Male Patientsb

Variables	Univariate analysis		Multivariate analysis^a
Variables	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Demographics
Age (years)	1.048 (1.027-1.070)	<0.001	—
History of smoking (yes vs no)	1.179 (0.654-2.127)	0.583	1.419 (0.771-2.611)	0.261
Past medical history
Diabetes (yes vs no)	0.561 (0.255-1.233)	0.150	0.495 (0.223-1.099)	0.084
Hypertension (yes vs no)	0.991 (0.459-2.138)	0.982	0.777 (0.352-1.715)	0.532
History of kidney disease (yes vs no)	0.435 (0.104-1.810)	0.252	0.379 (0.090-1.590)	0.185
History of encephalopathy (yes vs no)	0.763 (0.271-2.145)	0.608	0.524 (0.183-1.501)	0.229
History of respiratory disease (yes vs no)	1.091 (0.385-3.090)	0.870	0.750 (0.259-2.173)	0.596
History of heart disease (yes vs no)	0.452 (0.179-1.143)	0.093	0.325 (0.126-0.834)	0.019
Etiology of liver cirrhosis
HBV infection alone (yes vs no)	0.728 (0.390-1.359)	0.319	0.842 (0.448-1.585)	0.595
HCV infection alone (yes vs no)	2.050 (0.787-5.342)	0.142	1.541 (0.576-4.123)	0.389
Alcohol abuse alone (yes vs no)	0.904 (0.524-1.560)	0.716	0.969 (0.557-1.685)	0.911
Duration of liver cirrhosis (years)
<5	0.605 (0.326-1.124)	0.112	0.607 (0.325-1.135)	0.118
5-9	0.632 (0.276-1.444)	0.276	0.730 (0.316-1.686)	0.461
10-15	0.889 (0.209-3.788)	0.874	1.253 (0.287-5.473)	0.743

Abbreviations: NHC, non-hepatic cancers; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus. Bold indicates statistically significant of P-value.

^aAdjusted for age.

^bNon-cancer group as a reference group.

In female patients, univariate logistic regression analysis showed that older age (OR = 1.030; 95% CI = 1.010-1.070, P = 0.003), history of smoking (OR = 3.835; 95% CI = 1.876-7.842, P < 0.001), hypertension (OR = 2.119; 95% CI = 1.277-3.518, P = 0.004), and alcohol abuse alone as the etiology of liver cirrhosis (OR = 2.854; 95% CI = 1.212-6.722, P = 0.016) were significantly associated with a higher risk of NHC, but heart disease (OR = 0.380; 95% CI = 0.197-0.732, P = 0.004) was significantly associated with a lower risk of NHC. After adjusting for age, multivariate logistic regression analysis showed that history of smoking (OR = 3.672; 95% CI = 1.773-7.608, P < 0.001), hypertension (OR = 1.816; 95% CI = 1.079-3.056, P = 0.025), and alcohol abuse alone as the etiology of liver cirrhosis (OR = 2.997; 95% CI = 1.256-7.151, P = 0.013) were independently associated with a higher risk of NHC, but history of encephalopathy (aOR = 0.202; 95% CI = 0.048-0.854, P = 0.030) and heart disease (aOR = 0.295; 95% CI = 0.151-0.577, P < 0.001) were independently associated with a lower risk of NHC (Table 5).

Table 5.

Logistic Regression Analyses of Risk Factors of NHC in Female Patientsb

Variables	Univariate analysis		Multivariate analysis^a
Variables	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Demographics
Age (years)	1.030 (1.010-1.070)	0.003	—
History of smoking (yes vs no)	3.835 (1.876-7.842)	<0.001	3.672 (1.773-7.608)	<0.001
Past medical history
Diabetes (yes vs no)	1.100 (0.628-1.925)	0.739	0.988 (0.560-1.741)	0.966
Hypertension (yes vs no)	2.119 (1.277-3.518)	0.004	1.816 (1.079-3.056)	0.025
History of kidney disease (yes vs no)	0.423 (0.129-1.390)	0.156	0.429 (0.130-1.416)	0.165
History of encephalopathy (yes vs no)	0.254 (0.061-1.062)	0.060	0.202 (0.048-0.854)	0.030
History of respiratory disease (yes vs no)	0.509 (0.154-1.686)	0.269	0.423 (0.127-1.414)	0.162
History of heart disease (yes vs no)	0.380 (0.197-0.732)	0.004	0.295 (0.151-0.577)	<0.001
Etiology of liver cirrhosis
HBV infection alone (yes vs no)	0.738 (0.450-1.210)	0.228	0.851 (0.513-1.415)	0.535
HCV infection alone (yes vs no)	0.733 (0.354-1.517)	0.403	0.709 (0.341-1.473)	0.357
Alcohol abuse alone (yes vs no)	2.854 (1.212-6.722)	0.016	2.997 (1.256-7.151)	0.013
Duration of liver cirrhosis (years)
<5	1.154 (0.618-2.155)	0.654	1.180 (0.629-2.213)	0.606
5-9	1.153 (0.477-2.785)	0.752	1.233 (0.507-2.997)	0.644
10-15	1.333 (0.308-5.781)	0.701	1.367 (0.313-5.972)	0.677

Abbreviations: NHC, non-hepatic cancers; OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus. Bold indicates statistically significant of P-value.

^aAdjusted for age.

^bNon-cancer group as a reference group.

Discussion

Our study had several important findings. First, the prevalence of NHC and PLC was 6.22% and 22.20% in cirrhosis, respectively, which should be higher than that of cancer in the general population.²⁸ Moreover, the overall prevalence of NHC has been steadily increasing from 2011 to 2014, which highlights the necessity of cancer screening as well as surveillance in cirrhotic patients. This was likely driven by gradually increased recognition of various cancers and widespread use of advanced imaging techniques with greater diagnostic performance, and fueled by a higher probability of carrying more risk factors of cancers. Second, cirrhotic patients with a history of smoking had an increased risk of NHC nearly two-fold as compared to those without, and it remains a significant carcinogenic factor regardless of smoking status. Third, cirrhotic patients with encephalopathy or heart disease were less likely to develop NHC.

Previous studies showed that sex and age could influence the occurrence and development of cancer,^26,27 which was also confirmed in our univariate logistic regression analysis. Accordingly, we adjusted for sex and age in multivariate logistic regression analysis, showing that the NHC group had a significantly higher proportion of history of smoking than the non-cancer group. There are some possible explanations for this finding, as follows. First, there are many harmful chemicals in cigarettes, including PAH, N-nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes, and ethylene oxide, which are the major causes for various types of cancer.²⁹ These substances can directly or indirectly damage DNA, leading to genetic mutations in cells and ultimately developing cancer.³⁰ Second, smoking reduces the formation of cancer-suppressor-related proteins, thereby promoting cell proliferation.³¹ Furthermore, chemicals in tobacco can induce inflammatory response, which is closely related to the development of cancers.³²

Interestingly, our study found a reduction in the prevalence of NHC and PLC in cirrhotic patients with heart disease or encephalopathy. This might be because such patients need to take specific medications more frequently, such as aspirin, which can reduce the incidence and mortality of cancer.³³ In addition, cirrhotic patients with heart disease or encephalopathy might undergo screening more comprehensively, thereby initiating the intervention earlier and reducing the incidence of cancer. Another possible explanation is that patients with cardio-cerebral diseases often have lipid disorders,³⁴ thereby necessitating the use of lipid-regulating drugs, which are also potentially beneficial for anticancer effect by regulating lipids.^35-39 Our study also observed a diminished risk of PLC in cirrhotic patients with kidney and/or respiratory disease. This can be explained by the fact that the survival time is substantially shortened in such patients, compromising the development of cancer.

It has been shown that patients with HBV infection, HCV infection, or alcohol related liver cirrhosis have a higher risk of NHC.^10,40,41 By contrast, another study by Berman et al⁴² demonstrated that patients with cirrhosis secondary to viral hepatitis had a lower risk of NHC, whereas those with alcoholic cirrhosis had a higher risk of NHC. Our study showed no increased risk of NHC in patients with liver cirrhosis secondary to viral hepatitis or alcohol abuse. This discrepancy among studies might be attributed to the heterogeneity in the type of extrahepatic cancer observed and proportion of different cancers. Indeed, there are still some controversies about whether the incidence of certain cancers was increased in cirrhosis. Specifically, Su et al did not show that HBV infection related cirrhosis increased the risk of breast cancer,⁴³ Duberg et al did not demonstrate that HCV infection related cirrhosis increased the incidence of thyroid cancer,⁴⁴ and Sahlman et al⁴¹ did not find that alcohol abuse related cirrhosis increased the risk of lymphomas.

Previous studies suggested that patients with non-alcoholic cirrhosis were more likely to develop PLC.^45,46 Similarly, our study found that HBV infection alone was a risk factor for PLC in cirrhotic patients, whereas alcohol abuse alone might be a protective factor. However, in contrast to previous studies,⁴⁷ ours did not find that HCV infection alone was a risk factor for PLC in cirrhosis, probably due to a relatively small number of cirrhotic patients with HCV infection alone in our cohort.

We separately conducted an investigation into the risk factors associated with NHC in male and female patients. Female patients who smoked and consumed alcohol had an increased risk of NHC, which is consistent with our current knowledge that alcohol abuse in females can cause more medical problems.⁴⁸ Although its specific mechanism is unclear, there is a possible hypothesis that females have a lower proportion of body water than males of similar body weight, thereby causing a higher blood alcohol concentration after consuming an equivalent amount of alcohol.⁴⁹ Additionally, females have slower tobacco excretion due to their anatomy and higher level of dependence, thereby contributing to an increased risk of cancer.⁵⁰

Our study has comprehensively assessed the risk of NHC in liver cirrhosis, and has for the first time proposed that history of encephalopathy and/or heart disease may reduce the risk of NHC in patients with liver cirrhosis. This conclusion challenges the traditional knowledge that “comorbidities worsen prognosis” and provide new perspectives for subsequent research on the interactions among liver diseases, cancers, and chronic diseases. However, our study had several limitations as follows. First, this was a single-center retrospective study without external validity of its findings, which had selection bias and influenced the reliability of our findings. Second, the risk factors for cancers, such as body mass index, lifestyle habits, and other causes of cirrhosis, were not available and had not been analyzed yet. Third, we could not collect the frequency or amount of smoking and alcohol abuse in cirrhotic patients with a history of smoking and drinking, compromising further quantitative analysis.

Conclusion

The probability of NHC may be increased by smoking in cirrhosis, but compromised by the presence of encephalopathy or heart disease. These findings will be helpful for developing optimal strategies for screening and monitoring of cancer in cirrhosis. Certainly, more multicenter, prospective studies are warranted to further validate these conclusions.

Supplemental Material

Supplemental Material - Prevalence and Risk Factors for Non-Hepatic Cancers in Cirrhosis: A Cross-Sectional Study

Supplemental Material for Prevalence and Risk Factors for Non-Hepatic Cancers in Cirrhosis: A Cross-Sectional Study by Di Sun, Liyan Dong, Yue Sun, Yingchao Li, Junyuan Yin, Ran Wang, Deli Zou and Xingshun Qi in Cancer Control

Footnotes

Acknowledgments

This work has been partially presented as an oral abstract in the section “Public Health” of the Asian Pacific Association for the Study of the Liver (APASL) 2024.

Di Sun

Liyan Dong

Yue Sun

Yingchao Li

Junyuan Yin

Ran Wang

Deli Zou

Xingshun Qi

Ethical Considerations

The study protocol was reviewed and approved by the Medical Ethical Committee of the General Hospital of Northern Theater Command [Y (2024) 009] on January 22, 2024. The requirement for informed consent was waived due to the retrospective nature of this study.

Consent to Participate

Because of the retrospective nature of the study, the requirement for written informed consent was waived.

All authors have made an intellectual contribution to the manuscript and approved the submission.

Author Contributions

Conceptualization: Xingshun Qi

Formal analysis: Di Sun, Liyan Dong, Yingchao Li, and Xingshun Qi

Data curation: Di Sun, Liyan Dong, Yue Sun, Yingchao Li, Junyuan Yin, Deli Zou, and Xingshun Qi

Writing–original draft: Di Sun, Liyan Dong, Deli Zou, and Xingshun Qi

Writing–review and editing: Di Sun, Liyan Dong, Yue Sun, Yingchao Li, Junyuan Yin, Deli Zou, and Xingshun Qi

Supervision: Deli Zou, and Xingshun Qi.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The present study was supported by the Independent Research Funding of General Hospital of Northern Theater Command (ZZKY2024018), and Liaoning Provincial Science and Technology Plan Joint Plan (Technology Research and Attack Plan Project) (2024JH2/102600285).

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.*

Supplemental Material

Supplemental material for this article is available online.

Appendix

References

Romanelli

Stasi

. Recent advancements in diagnosis and therapy of liver cirrhosis. Curr Drug Targets. 2016;17(15):1804-1817.

GBD 2017 Cirrhosis Collaborators . The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266.

Gao

Ding

. Diagnosis and treatment of rare complications of liver cirrhosis. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese J Hepatol. 2020;28(5):372-376.

Kanwal

Khaderi

Singal

, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023;77(3):997-1005.

Toh

Wong

EYT

Wong

, et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology. 2023;164(5):766-782.

Ponvilawan

Charoenngam

Rujirachun

, et al. Chronic hepatitis C virus infection is associated with an increased risk of lung cancer: a systematic review and meta-analysis. Lung. 2020;198(4):705-714.

Kalaitzakis

Gunnarsdottir

Josefsson

Björnsson

. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(2):168-174.

Dalia

Chavez

Castillo

Sokol

. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013;37(9):1107-1115.

Wei

Qiu

Jin

, et al. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer. 2015;112(7):1283-1290.

10.

Sundquist

. Risk of hepatocellular carcinoma and cancers at other sites among patients diagnosed with chronic hepatitis B virus infection in Sweden. J Med Virol. 2014;86(1):18-22.

11.

Kamiza

Wang

Sung

Chang

Yeh

. Chronic hepatitis infection is associated with extrahepatic cancer development: a nationwide population-based study in Taiwan. BMC Cancer. 2016;16(1):861.

12.

Fiorino

Bacchi-Reggiani

de Biase

, et al. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2015;21(45):12896-12953.

13.

Goldacre

Wotton

Yeates

Seagroatt

Collier

. Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study. Eur J Gastroenterol Hepatol. 2008;20(5):384-392.

14.

Sorensen

Friis

Olsen

, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28(4):921-925.

15.

Torre

Siegel

Ward

Jemal

. Global cancer incidence and mortality rates and Trends--An update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16-27.

16.

Bray

Soerjomataram

. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. In: Gelband

Jha

Sankaranarayanan

Horton

, eds. Cancer: Disease Control Priorities. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank © 2015 International Bank for Reconstruction and Development / The World Bank; 2015.

17.

Glanz

Chen

Joffe

. Understanding risk factors for cancer: what's new and how can it help reduce the cancer burden? Cancer. 2022;128(19):3443-3445.

18.

McCormack

Boffetta

. Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011;22(11):2349-2357.

19.

Dong

Yin

, et al. No association of ABO blood groups and Rh factor with primary liver cancer in cirrhotic patients: a single-center cross-sectional study. Front Med. 2024;11:1432137.

20.

von Elm

Altman

Egger

Pocock

Gøtzsche

Vandenbroucke

. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.

21.

Han

, et al. Effect of admission time on the outcomes of liver cirrhosis with acute upper gastrointestinal bleeding: regular hours versus off-hours admission. Can J Gastroenterol Hepatol. 2018;2018:3541365.

22.

Mohamed

Abdelrahim

Elsayed

Shaaban

Eldahrouty

. Relationship between hepatitis C virus infection and extrahepatic malignancies. Clin Exp Hepatol. 2023;9(3):202-209.

23.

Gilles

Garbutt

Landrum

. Hepatocellular carcinoma. Crit Care Nurs Clin North Am. 2022;34(3):289-301.

24.

Piñero

Dirchwolf

Pessôa

. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370.

25.

Odenwald

Paul

. Viral hepatitis: past, present, and future. World J Gastroenterol. 2022;28(14):1405-1429.

26.

Dong

Cioffi

Wang

, et al. Sex differences in cancer incidence and survival: a pan-cancer analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1389-1397.

27.

Schwartz

. Epidemiology of cancer. Clin Chem. 2024;70(1):140-149.

28.

Zheng

Zeng

Zhang

Chen

. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370(1):33-38.

29.

Hecht

. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006;391(6):603-613.

30.

Phillips

. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis. 2002;23(12):1979-2004.

31.

Adler

Bahcheli

Cheng

KCL

, et al. Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes. Sci Adv. 2023;9(44):eadh3083.

32.

Gardi

Valacchi

. Cigarette smoke and ozone effect on murine inflammatory responses. Ann N Y Acad Sci. 2012;1259:104-111.

33.

Ricciotti

FitzGerald

. Aspirin in the prevention of cardiovascular disease and cancer. Annu Rev Med. 2021;72:473-495.

34.

Yang

Ren

, et al. Combinatory data-independent acquisition and parallel reaction monitoring method for revealing the lipid metabolism biomarkers of coronary heart disease and its comorbidities. J Sep Sci. 2024;47(8):e2300848.

35.

Watson

Dubois

. Lipid metabolism and APC: implications for colorectal cancer prevention. Lancet. 1997;349(9050):444-445.

36.

Martin-Perez

Urdiroz-Urricelqui

Bigas

Benitah

. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675-1699.

37.

Lei

Yang

, et al. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14(1):187.

38.

Jiang

Jin

. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.

39.

Alizadehasl

Alavi

Boudagh

, et al. Lipid-lowering drugs and cancer: an updated perspective. Pharmacol Rep. 2024;76(1):1-24.

40.

Bai

, et al. Patients with chronic hepatitis C virus infection are at an increased risk of colorectal cancer: a nationwide population-based case-control study in Taiwan. Front Oncol. 2020;10:561420.

41.

Sahlman

Nissinen

Pukkala

Färkkilä

. Cancer incidence among alcoholic liver disease patients in Finland: a retrospective registry study during years 1996-2013. Int J Cancer. 2016;138(11):2616-2621.

42.

Berman

Tandra

Vuppalanchi

, et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol. 2011;106(5):899-906.

43.

Chang

Chen

Sung

Yeh

. Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study. BMC Cancer. 2011;11:495.

44.

Duberg

Nordström

Törner

, et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology. 2005;41(3):652-659.

45.

Powell

Wong

Rinella

. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-2224.

46.

Mittal

El-Serag

Sada

, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124.e1-131.e1.

47.

Kumar

. MicroRNA in HCV infection and liver cancer. Biochim Biophys Acta. 2011;1809(11-12):694-699.

48.

Erol

Karpyak

. Sex and gender-related differences in alcohol use and its consequences: contemporary knowledge and future research considerations. Drug Alcohol Depend. 2015;156:1-13.

49.

Ely

Hardy

Longford

Wadsworth

. Gender differences in the relationship between alcohol consumption and drink problems are largely accounted for by body water. Alcohol Alcohol. 1999;34(6):894-902.

50.

Rahmanian

Diaz

Wewers

. Tobacco use and cessation among women: research and treatment-related issues. J Womens Health. 2011;20(3):349-357.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.08 MB

0.00 MB